Cytek Biosciences Valuation Multiples

Cytek Biosciences Overview

About Cytek Biosciences

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

Founded

2014

HQ

Employees

648

Website

cytekbio.com

Sectors

Medical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $203M

EBITDA: $335K

EV

$356M

Valuation Multiples

Multiples.vc

Start free trial

Cytek Biosciences Financials

Cytek Biosciences reported last 12-month revenue of $203M and EBITDA of $335K.

In the same LTM period, Cytek Biosciences generated $106M in gross profit, $335K in EBITDA, and had net loss of ($56M).

Cytek Biosciences P&L

In the most recent fiscal year, Cytek Biosciences reported revenue of $201M and EBITDA of $1M.

Cytek Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX

Cytek Biosciences Stock Performance

Cytek Biosciences has current market cap of $594M, and enterprise value of $356M.

Cytek Biosciences' stock price is $4.62.

Cytek Biosciences Valuation Multiples

Cytek Biosciences trades at 1.8x EV/Revenue multiple, and 1063.9x EV/EBITDA.

Cytek Biosciences Financial Valuation Multiples

As of April 11, 2026, Cytek Biosciences has market cap of $594M and EV of $356M.

Equity research analysts estimate Cytek Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Cytek Biosciences has a P/E ratio of (10.7x).

Cytek Biosciences Margins & Growth Rates

Cytek Biosciences' revenue in the last 12 month grew by 4%.

Cytek Biosciences' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.

Cytek Biosciences' rule of 40 is 2% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Cytek Biosciences' rule of X is 7% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Cytek Biosciences Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Cytek Biosciences M&A Activity

Cytek Biosciences acquired XXX companies to date.

Last acquisition by Cytek Biosciences was on XXXXXXXX, XXXXX. Cytek Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Cytek Biosciences Investment Activity

Cytek Biosciences invested in XXX companies to date.

Cytek Biosciences made its latest investment on XXXXXXXX, XXXXX. Cytek Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).